Bartlett NL, et al. - In patients with diffuse large B-cell lymphoma, researchers compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) vs standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regarding progression-free survival (PFS), response rate, overall survival (OS), and safety when administered as frontline therapy. In this phase III intergroup study, patients were administered six cycles of DA-EPOCH-R or R-CHOP. Findings revealed greater toxicity as well as no improvement in PFS or OS with the more intensive, infusional DA-EPOCH-R vs R-CHOP in this population. With R-CHOP, more favorable outcomes were obtained, vs historical controls, indicating a possible patient selection bias and could preclude generalizability of outcomes to specific risk subgroups.